Literature DB >> 12388816

Modification of primary and recurrent genital herpes in guinea pigs by passive immunization.

Nigel Bourne1, Richard B Pyles1, David I Bernstein1, Lawrence R Stanberry1.   

Abstract

Guinea pigs were administered antiserum 24 h (As+24) or 72 h (As+72) after intravaginal herpes simplex virus type 2 (HSV-2) challenge. Treatment at either time reduced acute virus replication in the dorsal root ganglia and the overall magnitude of replication in the genital tract. In two studies, As+24 treatment significantly reduced the severity of primary genital skin disease and the frequency of subsequent spontaneous recurrent disease. In contrast, As+72 treatment produced a modest reduction in primary disease severity but did not impact on recurrent disease. Quantitative PCR analysis of dorsal root ganglia DNA from latently infected animals showed that As+24 treatment produced a significantly reduced viral DNA burden, which appeared to correlate with the reduction in recurrent disease. The amount of DNA in the ganglia of As+72-treated animals was not significantly lower than that of controls. These observations have implications for both the dynamics of latency establishment and desirable vaccine characteristics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388816     DOI: 10.1099/0022-1317-83-11-2797

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  16 in total

1.  Using Split Luciferase Assay and anti-HSV Glycoprotein Monoclonal Antibodies to Predict a Functional Binding Site Between gD and gH/gL.

Authors:  Doina Atanasiu; Wan Ting Saw; Tina M Cairns; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2021-01-27       Impact factor: 5.103

2.  Development of disease and immunity at the genital epithelium following intrarectal inoculation of male guinea pigs with herpes simplex virus type 2.

Authors:  Nigel Bourne; Brianne N Banasik; Clarice L Perry; Aaron L Miller; Mellodee White; Richard B Pyles; Gregg N Milligan
Journal:  Virology       Date:  2018-11-06       Impact factor: 3.616

Review 3.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

Review 4.  Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?

Authors:  Gargi Dasgupta; Lbachir BenMohamed
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

Review 5.  The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.

Authors:  Tiffany Kuo; Christine Wang; Tina Badakhshan; Sravya Chilukuri; Lbachir BenMohamed
Journal:  Vaccine       Date:  2014-10-16       Impact factor: 3.641

6.  Long-term presence of virus-specific plasma cells in sensory ganglia and spinal cord following intravaginal inoculation of herpes simplex virus type 2.

Authors:  Gregg N Milligan; Michael G Meador; Chin-Fun Chu; Christal G Young; Talitha L Martin; Nigel Bourne
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms.

Authors:  Chin-Fun Chu; Michael G Meador; Christal G Young; Jane E Strasser; Nigel Bourne; Gregg N Milligan
Journal:  J Reprod Immunol       Date:  2007-10-24       Impact factor: 4.054

8.  Detection of herpes simplex virus type 2 (HSV-2) -specific cell-mediated immune responses in guinea pigs during latent HSV-2 genital infection.

Authors:  Clarice L Perry; Brianne N Banasik; Summer R Gorder; Jingya Xia; Sarah Auclair; Nigel Bourne; Gregg N Milligan
Journal:  J Immunol Methods       Date:  2016-09-19       Impact factor: 2.303

9.  Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes.

Authors:  Timothy Dudek; Lydia C Mathews; David M Knipe
Journal:  Virology       Date:  2007-11-19       Impact factor: 3.616

10.  A combined carrier-adjuvant system of peptide nanofibers and toll-like receptor agonists potentiates robust CD8+ T cell responses.

Authors:  Jai S Rudra; Brianne N Banasik; Gregg N Milligan
Journal:  Vaccine       Date:  2017-12-14       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.